Find a Tender
complete
Official procurement procedure
Herpes zoster (shingles) vaccine 2021
Vaccines
UK
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Department of Health and Social Care: "Herpes zoster (shingles) vaccine 2021". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | Department of Health and Social Care | Scope & Categories | Not published | Submission Window | complete No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: Department of Health and Social Care
Market Analytics
Derived from OCDS awards & bid statistics
Published history for Department of Health and Social Care. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Competition Density
11.8Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 451 active published awards; 397 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityDepartment of Health and Social Care | Procedure methodNot published | Procurement categoryNot published |
Statuscomplete | Framework / DPSNot published | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published15 Apr 2021, 11:29 BST | Last source update15 Apr 2021, 11:29 BST | Recurring procurementNot published |
ClassificationVaccines | ||
Delivery area UK | ||
OCIDocds-h6vhtk-02a63f | ||
What is being bought
The provision of Herpes zoster (shingles) vaccine
What changed
From the official release history
- Status changed to complete
15 Apr 2021, 11:29 BST - Official notice release published
15 Apr 2021, 11:29 BST - Buyer information updated
15 Apr 2021, 11:29 BST
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedcancelledPublished valueNot publishedThe provision of Herpes zoster (shingles) vaccine, deliveries will berequired from 1 April 2021 to 31 March 2023. Additional information: Value - this information is considered by the supplier to be commercially sensitive information. The authority is not publishing the value so as not to prejudice the legitimate commercial interest of the supplier.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
15 Apr 2021, 11:29 BST - Award active
Not published · Not published - Contract active
Signed 30 Mar 2021, 00:00 BST · £1
Commercial outcome and competition
Awards Merck Sharpe and Dohme (UK) Limited Not published · Not published · active |
Contracts Contract £1 · signed 30 Mar 2021, 00:00 BST · active |
Bid statistics bids: 1 (lot 1) |
Buyer and organisations in this procedure
Department of Health and Social Care
Contracting authority GB-FTS-43Documents (0)
Official links; attachments are not copied
No linked documents are published
Related procedures (0)
No related procedures published
Planning and rationale
Planning budgetNot published |
No-engagement rationaleNot published |
Procedure rationaleThere is only one supplier with an exclusive global licence to manufacture and distribute this vaccine which is licensed and approved for use in the UK and due to the functions of thevaccine, there is no reasonable alternative or substitute, therefore using the negotiated procedure without prior publication is justified under Regulation 32(2)(b)(ii) and (iii) of thePublic Contracts Regulations 2015 |